UCN2 and COVID-19: In a recent study assessing MSA and MAA prevalence in COVID-19 patients, an overall MSA and MAA prevalence of 2.4% was determined in healthy controls (n=41), yet neither anti-PM-Scl75, nor anti-Mi-2 beta, anti-SRP, and anti-TIF1g were positive in any controls (39).